幼年皮肌炎患者的生长与青春期发育:一项纵向队列研究
该跨国前瞻性纵向队列纳入196例活动期幼年皮肌炎患儿,分析身高、体重及青春期发育。女性及男性患者父母校正身高Z评分随时间显著下降,最终随访时出现追赶生长;但病程≥12个月女性无2年追赶生长,且青春期延迟和生长失败常见。
要点
- 活动期幼年皮肌炎患儿身高Z评分显著下降,但多数最终随访有追赶生长。
- 病程≥12个月女性患者无2年追赶生长,生长失败风险更高。
- 基线处于青春期早期者生长失败风险最高,需密切监测生长与青春期发育。
核心结论
- 活动期幼年皮肌炎和/或其治疗对患儿生长和青春期发育有显著影响。
- 近期进入青春期或既往有生长失败的患儿,青春期发育延迟和进一步生长迟缓的风险最高。
研究设计与样本
- 多国前瞻性纵向队列研究,纳入31个国家年龄<18岁的活动期幼年皮肌炎患儿。
- 对完成2年随访且有人体测量数据的196/275例(71%)患儿分析身高、体重和青春期发育。
主要发现
- 女性患者父母校正身高Z评分随时间显著下降(P<0.0001),男性患者亦显著下降(P=0.001),但最终随访时出现追赶生长。
- 中位BMI Z评分在6个月时达峰值(P<0.0001),最终随访(中位26个月)仍显著高于基线(P=0.007),两性间无差异。
- 病程≥12个月女性患者父母校正身高Z评分显著更低(P=0.002),且无2年追赶生长。
- 最终随访时生长失败见于20/97例女性(21%)和11/73例男性(15%);身高偏移(Δ身高Z评分<-0.25/年)见于29/116例女性(25%)和25/80例男性(31.3%)。
- 青春期延迟见于20/55例女性(36.4%)和11/31例男性(35.5%);基线处于青春期早期者生长失败风险最高。
临床怎么用
- 对活动期幼年皮肌炎患儿应常规监测身高、体重及青春期发育,尤其关注病程≥12个月的女性和基线青春期早期患儿。
- 对出现生长失败或青春期延迟的患儿,需考虑疾病活动及糖皮质激素等治疗的影响,并加强随访。
局限性
- 仅71%的患儿纳入分析,可能存在选择偏倚。
- 未报告具体治疗方案及其与生长结局的关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study growth and puberty in a multinational longitudinal prospective cohort of children with juvenile dermatomyositis (DM). METHODS: Children from 31 countries who were ages <18 years and had juvenile DM in active phase were studied, and analyses of height, weight, and pubertal development were conducted in those who had follow-up visits during a 2-year period and for whom anthropometric data was available. RESULTS: A total of 196 of 275 children (71%) were included. We found a significant reduction in parent-adjusted height Z score over time in female patients (P < 0.0001) and male patients (P = 0.001), but with catch-up growth at the final study visit. Median body mass index Z score peaked at 6 months (P < 0.0001) and was still significantly above baseline at the final study visit, which was at a median of 26 months after baseline (P = 0.007), with no difference between sexes. Female patients with a disease duration ≥12 months after onset had significantly lower parent-adjusted height Z score (P = 0.002) and no 2-year catch-up growth. At the final study visit, growth failure was seen in 20 of 97 female patients (21%) and in 11 of 73 male patients (15%). Height deflection (∆height Z score less than -0.25/year) was observed in 29 of 116 female patients (25%) and 25 of 80 male patients (31.3%). Delayed puberty was seen in 20 of 55 female patients (36.4%) and in 11 of 31 male patients (35.5%). Children in early pubertal stage at baseline had the highest risk of growth failure. CONCLUSION: Juvenile DM in the active phase and/or its treatment has a significant impact on growth and puberty in affected children. Children with recent onset of puberty or previous growth failure have the highest risk of delayed pubertal development and further growth retardation.
引用
- Nordal E, Pistorio A, Rygg M, et al. Growth and Puberty in Juvenile Dermatomyositis: A Longitudinal Cohort Study. Arthritis Care Res (Hoboken). 2020. PMID: 31507092. doi:10.1002/acr.24065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。